{"id":"NCT02858440","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","officialTitle":"Immunogenicity and Safety of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-13","primaryCompletion":"2017-10-24","completion":"2018-11-13","firstPosted":"2016-08-08","resultsPosted":"2019-07-19","lastUpdate":"2019-09-24"},"enrollment":235,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix-IPV/Hib","otherNames":[]}],"arms":[{"label":"DTPa-IPV/Hib Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and as a booster dose at 18 months of age in Russian healthy children according to the Russian immunisation schedule","primaryOutcome":{"measure":"Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T), Post Primary Vaccination","timeFrame":"At Month 4 (i.e. one month after 3rd dose of primary vaccination)","effectByArm":[{"arm":"DTPa-IPV/Hib Group","deltaMin":176,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":["32048889"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":235},"commonTop":["Irritability postvaccinal","Injection site erythema","Somnolence","Injection site pain","Injection site swelling"]}}